Data mining analysis of miR-638 and key genes interaction in cisplatin resistant triple-negative breast cancer
Cisplatn is one of the chemotherapy for the treatment of triple‐negatve breast cancer (TNBC), but its effectveness is limited because of the phenomenon of chemoresistance. miR‐638 was shown to regulate chemoresistance; however, it has never been validated in the cisplatn‐resistant tumor from patents....
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universitas Gadjah Mada, Yogyakarta
2019-12-01
|
| Series: | Indonesian Journal of Biotechnology |
| Subjects: | |
| Online Access: | https://jurnal.ugm.ac.id/ijbiotech/article/view/48732 |
| _version_ | 1811171036326002688 |
|---|---|
| author | Adam Hermawan Herwandhani Putri |
| author_facet | Adam Hermawan Herwandhani Putri |
| author_sort | Adam Hermawan |
| collection | DOAJ |
| description | Cisplatn is one of the chemotherapy for the treatment of triple‐negatve breast cancer (TNBC), but its effectveness is limited because of the phenomenon of chemoresistance. miR‐638 was shown to regulate chemoresistance; however, it has never been validated in the cisplatn‐resistant tumor from patents. This present study aimed to identfy the key gene regulatory networks of miR‐638 and evaluate the potental role of the miR‐638 and its targets as potental prognosis biomarkers for cisplatn‐resistance triple‐negatve breast cancer patents. The miR‐638 target was obtained from the miRecords database while the mRNA of chemoresistance biomarker candidate was obtained from the GSE18864 of GEO database, which is mRNA of cisplatn‐resistance TNBC patents. CCND1 and FZD7 are potental candidates for cisplatn chemoresistance biomarkers in patents with TNBC. Moreover, a Kaplan‐Meier survival plot showed that breast cancer patents with low mRNA levels of FZD7 had signifcantly worse overall survival than those in higher mRNA expression group. Taken together, miR‐638 plays a role in cisplatn resistance mechanism through a mechanism involving its target gene CCND1 and FZD7. Overall, miR‐638, CCND1, and FZD7 are candidates for cisplatn biomarker resistance in TNBC. |
| first_indexed | 2024-04-10T17:07:56Z |
| format | Article |
| id | doaj.art-ee4cad7041a844f9bc9e7790c22b5469 |
| institution | Directory Open Access Journal |
| issn | 0853-8654 2089-2241 |
| language | English |
| last_indexed | 2024-04-10T17:07:56Z |
| publishDate | 2019-12-01 |
| publisher | Universitas Gadjah Mada, Yogyakarta |
| record_format | Article |
| series | Indonesian Journal of Biotechnology |
| spelling | doaj.art-ee4cad7041a844f9bc9e7790c22b54692023-02-06T02:59:57ZengUniversitas Gadjah Mada, YogyakartaIndonesian Journal of Biotechnology0853-86542089-22412019-12-01242657310.22146/ijbiotech.4873225884Data mining analysis of miR-638 and key genes interaction in cisplatin resistant triple-negative breast cancerAdam Hermawan0Herwandhani Putri1Laboratory of Macromolecular Engineering, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara II, Yogyakarta 55281Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada, Sekip Utara II, Yogyakarta 55281Cisplatn is one of the chemotherapy for the treatment of triple‐negatve breast cancer (TNBC), but its effectveness is limited because of the phenomenon of chemoresistance. miR‐638 was shown to regulate chemoresistance; however, it has never been validated in the cisplatn‐resistant tumor from patents. This present study aimed to identfy the key gene regulatory networks of miR‐638 and evaluate the potental role of the miR‐638 and its targets as potental prognosis biomarkers for cisplatn‐resistance triple‐negatve breast cancer patents. The miR‐638 target was obtained from the miRecords database while the mRNA of chemoresistance biomarker candidate was obtained from the GSE18864 of GEO database, which is mRNA of cisplatn‐resistance TNBC patents. CCND1 and FZD7 are potental candidates for cisplatn chemoresistance biomarkers in patents with TNBC. Moreover, a Kaplan‐Meier survival plot showed that breast cancer patents with low mRNA levels of FZD7 had signifcantly worse overall survival than those in higher mRNA expression group. Taken together, miR‐638 plays a role in cisplatn resistance mechanism through a mechanism involving its target gene CCND1 and FZD7. Overall, miR‐638, CCND1, and FZD7 are candidates for cisplatn biomarker resistance in TNBC.https://jurnal.ugm.ac.id/ijbiotech/article/view/48732mir-638chemoresistancetriple-negative breast cancerdata mining |
| spellingShingle | Adam Hermawan Herwandhani Putri Data mining analysis of miR-638 and key genes interaction in cisplatin resistant triple-negative breast cancer Indonesian Journal of Biotechnology mir-638 chemoresistance triple-negative breast cancer data mining |
| title | Data mining analysis of miR-638 and key genes interaction in cisplatin resistant triple-negative breast cancer |
| title_full | Data mining analysis of miR-638 and key genes interaction in cisplatin resistant triple-negative breast cancer |
| title_fullStr | Data mining analysis of miR-638 and key genes interaction in cisplatin resistant triple-negative breast cancer |
| title_full_unstemmed | Data mining analysis of miR-638 and key genes interaction in cisplatin resistant triple-negative breast cancer |
| title_short | Data mining analysis of miR-638 and key genes interaction in cisplatin resistant triple-negative breast cancer |
| title_sort | data mining analysis of mir 638 and key genes interaction in cisplatin resistant triple negative breast cancer |
| topic | mir-638 chemoresistance triple-negative breast cancer data mining |
| url | https://jurnal.ugm.ac.id/ijbiotech/article/view/48732 |
| work_keys_str_mv | AT adamhermawan datamininganalysisofmir638andkeygenesinteractionincisplatinresistanttriplenegativebreastcancer AT herwandhaniputri datamininganalysisofmir638andkeygenesinteractionincisplatinresistanttriplenegativebreastcancer |